

C1
4. The method of Claim 1, in which the compound is a mimic of Endothelin-1 that selectively binds to the endothelin B receptor.

16. A method for treating cancer comprising administering a compound that is a selective antagonist to an endothelin B receptor such that it prevents the downregulation of β -catenin in the cancer cell to a patient in need of such treatment.

17. A method for treating cancer comprising administering a compound that is a selective antagonist to an endothelin B receptor such that it prevents the downregulation of p120^{CTN} in the cancer cell to a patient in need of such treatment.

C2
18. A method for treating cancer comprising administering a compound that is a selective antagonist to an endothelin B receptor such that it prevents the increased activity of caspase 8 in the cancer cell to a patient in need of such treatment.

19. The method of claim 1 wherein the compound that is a selective antagonist to an endothelin B receptor is determined by an *in vitro* assay comprising:

a) contacting a cell expressing endothelin B receptor and E-cadherin with endothelin and the compound; and

b) determining the level of E-cadherin expression,
wherein the level of E-cadherin expression in cells contacted with endothelin in the absence of the compound is decreased compared to the level of E-cadherin expression in cells contacted with endothelin and the compound.